HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

Otto Metzger Filho,Giuseppe Viale,Lorenzo Trippa,Tianyu Li,Denise A. Yardley,Ingrid A. Mayer,Vandana G. Abramson,Carlos L. Arteaga,Laura Spring,Adrienne G. Waks,Michalina Janiszewska,Eileen Wrabel,Michelle Demeo,Aditya Bardia,Tari A. King,Kornelia Polyak,Eric P. Winer,Ian E. Krop

HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

2019

Otto Metzger Filho
Giuseppe Viale
Lorenzo Trippa
Tianyu Li
Denise A. Yardley
Ingrid A. Mayer
Vandana G. Abramson
Carlos L. Arteaga
Laura Spring
Adrienne G. Waks
Michalina Janiszewska
Eileen Wrabel
Michelle Demeo
Aditya Bardia
Tari A. King
Kornelia Polyak
Eric P. Winer
Ian E. Krop

502Background: HER2 targeted therapywithout chemotherapy may be insufficient to completely eradicate a HER2+ cancer in cases of significant intratumor HER2 heterogeneity (ITH-HER2). Methods: We co...

Keywords:

Physical therapy
Oncology
Clinical trial
Pertuzumab
Internal medicine
Medicine
Targeted therapy
Cancer
Pathology
Chemotherapy

Correction
Source
Cite
Save

References

Citations